Agents targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) [ipilimumab] and programmed cell death receptor 1 (PD-1) (nivolumab, pembrolizumab) or its ligand programmed cell death ligand 1 (PD-L1) [durvalumab, atezolizumab] have been approved for treatment of advanced NSCLC [1]. Here, CD274 is linked to non-small cell lung carcinoma.